Duke Clinical Research Institute, Duke University Medical Center, Durham, NC.
Am Heart J. 2013 Sep;166(3):559-65. doi: 10.1016/j.ahj.2013.05.025. Epub 2013 Aug 15.
In ARISTOTLE, apixaban resulted in a 21% reduction in stroke, a 31% reduction in major bleeding, and an 11% reduction in death. However, approval of apixaban was delayed to investigate a statement in the clinical study report that "7.3% of subjects in the apixaban group and 1.2% of subjects in the warfarin group received, at some point during the study, a container of the wrong type."
Rates of study medication dispensing error were characterized through reviews of study medication container tear-off labels in 6,520 participants from randomly selected study sites. The potential effect of dispensing errors on study outcomes was statistically simulated in sensitivity analyses in the overall population.
The rate of medication dispensing error resulting in treatment error was 0.04%. Rates of participants receiving at least 1 incorrect container were 1.04% (34/3,273) in the apixaban group and 0.77% (25/3,247) in the warfarin group. Most of the originally reported errors were data entry errors in which the correct medication container was dispensed but the wrong container number was entered into the case report form. Sensitivity simulations in the overall trial population showed no meaningful effect of medication dispensing error on the main efficacy and safety outcomes.
Rates of medication dispensing error were low and balanced between treatment groups. The initially reported dispensing error rate was the result of data recording and data management errors and not true medication dispensing errors. These analyses confirm the previously reported results of ARISTOTLE.
在 ARISTOTLE 研究中,阿哌沙班使卒中风险降低 21%,大出血风险降低 31%,全因死亡风险降低 11%。然而,阿哌沙班的批准被推迟,以调查临床研究报告中的一项声明,即“阿哌沙班组的 7.3%和华法林组的 1.2%受试者在研究期间的某个时间点接受了错误类型的容器的药物。”
通过对来自随机选择的研究地点的 6520 名参与者的研究药物容器撕下标签进行审查,对研究药物配药错误率进行了特征描述。在总体人群中进行了敏感性分析,对配药错误对研究结果的潜在影响进行了统计学模拟。
导致治疗错误的配药错误率为 0.04%。阿哌沙班组和华法林组中至少接受 1 个错误容器的参与者比例分别为 1.04%(34/3273)和 0.77%(25/3247)。最初报告的大多数错误是数据录入错误,其中正确的药物容器被配发,但错误的容器编号被输入病例报告表。在整个试验人群中的敏感性模拟显示,配药错误对主要疗效和安全性结局没有明显影响。
配药错误率较低,且两组之间平衡。最初报告的配药错误率是数据记录和数据管理错误的结果,而不是真正的配药错误。这些分析证实了 ARISTOTLE 先前报告的结果。